enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGN) was the recipient of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 922,661 shares, a decline of 25.3% from the February 26th total of 1,235,753 shares. Based on an average daily volume of 906,038 shares, the short-interest ratio is presently 1.0 days. Currently, 1.5% of the shares of the company are short sold.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ENGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Jefferies Financial Group initiated coverage on shares of enGene in a research note on Friday, January 30th. They set a “buy” rating and a $28.00 price target for the company. Wall Street Zen upgraded shares of enGene from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of enGene in a research report on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, enGene has an average rating of “Moderate Buy” and an average target price of $22.86.

enGene Stock Down 3.0%

ENGN stock traded down $0.19 during midday trading on Monday, reaching $6.18. 140,104 shares of the company’s stock traded hands, compared to its average volume of 425,575. The company has a market cap of $413.97 million, a price-to-earnings ratio of -2.75 and a beta of -0.29. The firm’s fifty day moving average price is $9.06 and its 200-day moving average price is $8.31. enGene has a 52 week low of $2.65 and a 52 week high of $12.25. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.11. As a group, sell-side analysts forecast that enGene will post -1.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On enGene

Several large investors have recently modified their holdings of ENGN. Cresset Asset Management LLC purchased a new stake in enGene in the 2nd quarter worth approximately $36,000. Affinity Asset Advisors LLC purchased a new stake in shares of enGene in the second quarter worth $280,000. Paloma Partners Management Co purchased a new stake in shares of enGene in the second quarter worth $38,000. PFS Partners LLC bought a new stake in enGene during the third quarter valued at $61,000. Finally, Raymond James Financial Inc. grew its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after buying an additional 7,932 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.